Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology (2025)
- Authors:
- USP affiliated authors: ULRICH, ALEXANDER HENNING - IQ ; BRITTO, LUIZ ROBERTO GIORGETTI DE - ICB ; FERREIRA, ANA FLAVIA FERNANDES - ICB
- Unidades: IQ; ICB
- DOI: 10.1007/s12035-024-04611-9
- Subjects: DELEÇÃO DE GENES; DOENÇA DE PARKINSON; RATOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Molecular Neurobiology
- ISSN: 0893-7648
- Volume/Número/Paginação/Ano: v. 62, p. 5333-5346, 2025
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
FERREIRA, Ana Flávia Fernandes et al. Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology. Molecular Neurobiology, v. 62, p. 5333-5346, 2025Tradução . . Disponível em: https://dx.doi.org/10.1007/s12035-024-04611-9. Acesso em: 11 fev. 2026. -
APA
Ferreira, A. F. F., Ulrich, H., Mori, Y., Feng, Z. -P., Sun, H. -S., & Britto, L. R. G. de. (2025). Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology. Molecular Neurobiology, 62, 5333-5346. doi:10.1007/s12035-024-04611-9 -
NLM
Ferreira AFF, Ulrich H, Mori Y, Feng Z-P, Sun H-S, Britto LRG de. Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology [Internet]. Molecular Neurobiology. 2025 ; 62 5333-5346.[citado 2026 fev. 11 ] Available from: https://dx.doi.org/10.1007/s12035-024-04611-9 -
Vancouver
Ferreira AFF, Ulrich H, Mori Y, Feng Z-P, Sun H-S, Britto LRG de. Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology [Internet]. Molecular Neurobiology. 2025 ; 62 5333-5346.[citado 2026 fev. 11 ] Available from: https://dx.doi.org/10.1007/s12035-024-04611-9 - Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model
- Deletion of the transient receptor potential melastatin 2 gene mitigates the 6-hyydroxydopamine-induced Parkinson’s Disease–Like Pathology
- The role of interleukin-17 in neurological disorders
- Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model
- The transient receptor potential melastatin 2: a new therapeutical target for Parkinson’s disease?
- Inhibition of TRPM2 by AG490 is neuroprotective in a Parkinson’s Disease animal model
- Purinergic signaling in Parkinson’s disease
- Proliferation and differentiation of embryonic cells to neurons depende on purinergic receptor-induced calcium transients
- Carvacrol promotes neuroprotection in the mouse hemiparkinsonian model
- Pharmacological properties of purinergic receptors and their effects on proliferation and induction of neuronal differentiation of P19 embryonal carcinoma cells
Informações sobre o DOI: 10.1007/s12035-024-04611-9 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
3236167.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
